In a clinical trial of semaglutide injection for weight loss (Wegovy) in patients with T2DM and a BMI of 27 kg/m2 or more, hypoglycemia (defined as a plasma glucose less than 54 mg/dL) was reported in 6.2% of semaglutide-treated patients versus 2.5% of placebo-treated patients
She Annette Bennett Chief Executive Officer Bo Vaughan is a native of Richmond, VA and forward-thinking health care strategist with a Bo Vaughan, MD, MSHA, CPI Medical Director Mimi Franzen Canada Chief Operations Officer Jeanette Weller EVP of Contracts and Budgets Caitlin Vining Controller CCRP Kelly Craighead, BS, RN, CCRC Regulatory Affairs Director Carly McLaughlin, PharmD Director of Pharmacy PharmD Lisa Smith, BSN, RN Director of Quality Assurance Joy Walker Director of Business Development Aundraya Bray, LCSW Clinical Operations Coordinator Shawn Mease, CCRC, NRP, CCEMT-P Director of Study Start-Up
Another promising property of Madecassoside is that it seems to inhibit UV-induced melanin synthesis (test formula with 0.05% MA, used twice a day on 23 volunteers for 8 weeks), making it a great active for hyperpigmentation-prone skin
Zwart, P
